NEJM

Intermune’s Nintedanib Found Effective in Fatal Lung Disease

Intermune’s Nintedanib Found Effective in Fatal Lung Disease

Intermune Inc.’s pirfenidone and nintedanib have been found helpful in cases of a fatal lung disease that generally causes death in three to five years. Two separate studies have found the cancer treatment drug having a positive impact in reducing the progression of idiopathic pulmonary fibrosis.

Location: 
Laboratories: 
Company: 

Diabetes Related Health Complications Lower Among U.S. Adults

Diabetes Related Health Complications Lower Among U.S. Adults

CDC data suggests that health complications related to diabetes have seen a decline in the last two decades. The instances of heart attack, stroke and kidney ailments related to diabetes among U.S. adults have reduced by a big percentage as per the report of US Health Agency.

Between 1990 and 2010, the heart attacks caused by high blood sugar have reduced by nearly 70 percent. The stroke cases related to diabetes have also reduced by 50 percent. The end-stage kidney ailments, which require dialysis or kidney transplant have also reduced by 28 percent as per data recorded by CDC.

Laboratories: 
News: 
Location: 

Experimental Hepatitis Drug Cures 95% Patients in Clinical Trial: German Researchers

Experimental Hepatitis Drug Cures 95% Patients in Clinical Trial

German and US Research team has announced 95 percent success rate for an experimental drug for treatment of Hepatitis C. The drug has been found effective even in patients who failed to respond to earlier treatment. The experimental drug therapy has been reported to be better-tolerated by patients, over a period of three months compared to interferon treatment which generally requires one year.

Laboratories: 
Company: 

New Guidelines on Statin use in United States

New Guidelines Statin Offer access to 13 Million More Americans

As per latest guidelines by the American Heart Association (AHA), 13 million additional Americans are at an increased risk of developing heart disease with an age older than 60 years. The new guidelines recommend cholesterol-lowering statin drugs for these individuals. Recently, the guidelines were revised on risk factors for heart disease and stroke by the AHA and the American College of Cardiology last November.

The new guidelines state that if a person is at 7.5% increased risk of developing heart disease in next 10 years, he must be recommended statins.

News: 
Location: 

DNA Blood Test Helps in Detecting Down Syndrome in Nine to Ten Weeks Fetus

DNA Blood Test Helps in Detecting Down Syndrome in Nine to Ten Weeks Fetus

A new DNA test of the blood of pregnant women is more successful in detecting Down syndrome and other common disorders in nine to 10 weeks old fetus compared to current screening methods. About 200,000 other invasive tests like amniocentesis or chronic villus sampling are conducted every year to diagnose for disorders in fetus, but all these procedures increase the risks of miscarriage.

Laboratories: 
News: 

Obesity in Teens Starts at Age of Five: NEJM Study

Obesity in Teens Starts at Age of Five: NEJM Study

The research published in the New England Journal of Medicine states that child’s ‘weight fate’ starts at age of five i.e. its kindergarten age. Obesity has been an issue of concern from past many years, with about 33% of US kids is obese in the US.
A nationwide survey of more than 7,700 children through grade school was conducted by researchers. Initially, 12% of kindergarten children were obese with 15% overweight, which later on found to be 21% obese and 17% overweight when they reached eighth grade.

News: 

Solanezumab and bapineuzumab fail in Trials for Alzheimer’s disease

Solanezumab and bapineuzumab fail in Trials for Alzheimer’s disease

Eli Lilly’s solanezumab and J&J’s bapineuzumab have failed in phase III trials on patients suffering from mild to moderate dementia. The trials have not found noticeable improvement in cognitive abilities of the study subjects.

Bapineuzumab trial was carried out of 2200 patients while 2000 patients participated in solanezumab trial. Eli Lilly announced that the company will carry out another trial of solanezumab but bapineuzumab trials have been halted.

Laboratories: 

New Drug Shows Promising Results for Genital Herpes

New Drug Shows Promising Results for Genital Herpes

German pharmaceutical company AiCuris has funded a study which recorded good results among patients suffering from genital herpes. With the discovery of new drug, the painful condition of genital herpes caused by Herpes simplex virus can be kept under control. Till date, there was no permanent treatment for genital herpes, only it could be suppressed.

Location: 
News: 
Company: 

RotaTeq and Rotarix Termed Safer Vaccines for Rotavirus

RotaTeq and Rotarix Termed Safer Vaccines for Rotavirus

New study published in NEJM has found GlaxoSmithKline’s Rotarix and Merck AG’s RotaTeq as safer vaccines for deadly rotavirus which impacts young kids in developing and poor nations. The first rotavirus vaccine was pulled from the market due to higher number of intussusception cases. CDC in United States has found the two new vaccines much safer, with less side effects, based on 1.5 million doses administered.

Laboratories: 
News: 
Company: 

Popular Stories

Harley-Davidson to turn 8 Dyna motorbikes into new Softail bikes

Betting big on cruisers, the luxury motorcycle... Read More

Uber’s net loss declines as ride bookings grow

Uber Technologies reported lower loss by nearly 9... Read More

Samsung Galaxy Note 8 facing challenges on multiple fronts

The Samsung Galaxy Note 8 is facing an increasingly... Read More

Leaked reports reveal more about new BMW M5

Luxury carmaker BMW’s next-generation M5 car will... Read More